Tscan Therapeutics Intrinsic Value Calculation – TSCAN THERAPEUTICS Director Makes Significant Investment in Company, Purchasing 29,147 Shares
December 23, 2023
☀️Trending News
TSCAN THERAPEUTICS ($NASDAQ:TCRX) is a biotechnology company focused on the development of treatments for cancer, autoimmune, and inflammatory diseases. Recently, the company’s director has revealed that they have purchased 29,147 shares in the company. The purchase of the shares serves as an indication of the confidence that the director has in the potential of TSCAN THERAPEUTICS to create innovative treatments for a variety of diseases. The investment by the director is a bold move and shows that they believe in the promise of TSCAN THERAPEUTICS. This investment will undoubtedly help to further the research and development of treatments for cancer, autoimmune, and inflammatory diseases.
It is expected that this purchase will be beneficial to both the company as well as shareholders. The investment by the director of TSCAN THERAPEUTICS is a strong signal of their commitment to furthering their research and development. This purchase speaks to their confidence in the potential of the company’s treatments to help people who suffer from cancer, autoimmune, and inflammatory diseases. With this investment, TSCAN THERAPEUTICS is one step closer to creating treatments that will improve the lives of patients around the world.
Share Price
On Friday, TSCAN THERAPEUTICS Director, Mr. Lee, made a significant investment in the company by purchasing 29,147 shares of the company’s common stock. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Tscan Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 16.93 | -88.33 | -521.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tscan Therapeutics. More…
| Operations | Investing | Financing |
| -53.6 | -64.05 | 135.53 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tscan Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 291.38 | 122.42 | 3.53 |
Key Ratios Snapshot
Some of the financial key ratios for Tscan Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -498.7% |
| FCF Margin | ROE | ROA |
| -340.5% | -29.4% | -18.1% |
Analysis – Tscan Therapeutics Intrinsic Value Calculation
At GoodWhale, we have conducted an analysis of TSCAN THERAPEUTICS‘s wellbeing. After thoroughly reviewing the company’s financials and other relevant information, our proprietary Valuation Line has determined that the fair value of TSCAN THERAPEUTICS’ share is around $3.2. Interestingly, the current stock price of the company is particularly high at $5.8, representing an overvaluation of 83.1%. We believe this discrepancy presents a great opportunity for investors to capitalize on the mispriced security. More…
Peers
TScan Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of its proprietary T cell receptor scanning technology for the treatment of cancer and autoimmune diseases. The company’s primary competitors are Freeline Therapeutics Holdings PLC, PhaseBio Pharmaceuticals Inc, and Werewolf Therapeutics Inc.
– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)
Freeline Therapeutics Holdings PLC is a biopharmaceutical company that focuses on the development and commercialization of gene therapies for chronic liver diseases. The company has a market cap of $42.89 million and a return on equity of -1.18%. Freeline’s lead product candidate, FLT180a, is in clinical development for the treatment of hemophilia B and other bleeding disorders. The company is also developing FLT190 for the treatment of Wilson disease.
– PhaseBio Pharmaceuticals Inc ($NASDAQ:PHAS)
Bio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company’s lead product candidate is BIO-1402, a small molecule inhibitor of the PI3K/mTOR pathway. The company’s second product candidate is BIO-1210, a small molecule inhibitor of the HDAC family of enzymes.
– Werewolf Therapeutics Inc ($NASDAQ:HOWL)
Werewolf Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company’s lead product candidate, WTX-124, is a monoclonal antibody that targets the protein CD47, which is overexpressed on the surface of cancer cells and inhibits the body’s natural immune response to cancer. Werewolf Therapeutics is currently conducting a Phase 1/2 clinical trial of WTX-124 in patients with solid tumors.
The company’s market cap as of 2022 is 112.8M. The company has a Return on Equity of -28.8%.
Summary
Investors in TScan Therapeutics should take note of recent director activity, as one director purchased 29,147 shares of the company’s stock on an unspecified date. This was likely a positive sign, as the stock price increased on the same day. In the coming quarters, investors should pay close attention to the company’s financial performance, sales and marketing, and product development activities. If the company can continue to generate attractive returns for shareholders, then the stock should continue to be a solid long-term investment.
